- Home
- BMR vs BYSI Comparison
BMR vs BYSI Comparison
Compare BMR & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMR | BYSI |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.9M | 67.9M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | BMR | BYSI |
|---|---|---|
| Price | $1.54 | $1.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 75.5K | 22.2K |
| Earning Date | 02-26-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.49 | $0.98 |
| 52 Week High | $4.32 | $3.44 |
Technical Indicators
Market Signals| Indicator | BMR | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 41.17 | 57.41 |
| Support Level | N/A | $1.38 |
| Resistance Level | $1.94 | $1.83 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 16.39 | 67.62 |
Price Performance
Historical ComparisonAbout BMR Beamr Imaging Ltd.
Beamr Imaging Ltd is a video technology and image science software company. It is an innovator of video encoding, transcoding, and optimization solutions that enable high quality, performance, and unmatched bitrate efficiency for video and images. The company is conducted through one operating segment, the optimization technology for video and photo compression. The company operates in Israel, the United States, and the rest of the world, it derives a majority of its revenue from the United States.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.